In this Global CTE Summit session on progress toward diagnosing CTE during life, Dr. @NicholasAshton shares findings from Banner Research's Fluid Biomarker Program.

Dr. Ashton & colleagues are exploring how techniques used to detect Alzheimer's may be applicable for CTE.

This multi-center study demonstrates that dried and capillary blood as a minimally invasive, scalable approach for #Alzheimers #biomarker testing in research, with potential for widely scalable population-based research, especially in resource-limited settings. @NicholasAshton @wagnersbrum
nature.com/articles/s4159…

New @Nature
Detection of Alzheimer's pathology from a dried blood spot derived from capillaries with capability of quantifying p-tau217 and other neuromarker levels
nature.com/articles/s4159…

The p-tau217 biomarker by age and prevalence of Alzheimer's disease in the community of ~12,000 people in Norway
nature.com/articles/s4158…

'The study also found that people with lower education levels have higher p-Tau217 levels.
“That finding kind of took my breath away”
nature.com/articles/d4158…

Hot off the press!
P-Tau 217 has been measured in over 11,000 participants and prevalence of #AlzheimersDisease pathology has been characterised
nature.com/articles/s4158…
@AarslandDag @NicholasAshton @KingsIoPPN @Nature

p-tau217, the breakthrough blood test, prediction of amyloid-β burden and Alzheimer's disease in people with no symptoms, no cognitive impairment
jamanetwork.com/journals/jaman…

Really excited to our announce the publication of our meta-analysis of p-tau217 differences in amyloid pos/neg cognitively unimpaired individuals. Very honored to have co-authored this with @NicholasAshton! pubmed.ncbi.nlm.nih.gov/41324928/

Our new meta-analysis for plasma p-tau217 for detecting preclinical Alzheimer’s pathology in cogntively unimpaired older adults
🩸🧠🧪📈

pubmed.ncbi.nlm.nih.gov/41324928/

We tested 6 p-tau217 assays to see if serum can replace plasma.
✔️ Lumipulse showed near-perfect correlation (ρ=0.98)
⚠️ Serum needs its own cutoffs

Bottom line: Serum p-tau217 is ready for wider clinical + research use—with proper validation

pubmed.ncbi.nlm.nih.gov/41231544/

Diagnosing Alzheimer’s in adults with Down syndrome is tough—but crucial. In 2329 participants, plasma #pTau217 had high accuracy for AD pathology in this high-risk population.

#AlzheimersDisease #DownSyndrome #Biomarkers #pTau217 #Neurodegeneration

pubmed.ncbi.nlm.nih.gov/41213934/

Why does this matter?
Knowing when biomarkers change helps us stage disease and optimize timing for treatments—crucial for trials & patients. (6/6)
🙏 Thanks to all collaborators!
@NicholasAshton @SebastianPalmqv @OskarHansson9 @biofinder_study

Learn about #brainhealth and navigate advances in #AlzheimersDisease with this two-part workshop series at #GSA2025. Join us on 11/13 at 11:30 AM EST & 11/14 at 6:00 AM EST bit.ly/Boston25-T #Gerontology @_BrightFocus @NicholasAshton @mboustan @BarakGaster @ScottKaiserMD

🚨Just published in @NatureNeuro🚨

Led by @jpfsouza33, this study used imaging & fluid biomarkers to reveal that microglia modulate Aβ-related astrocyte reactivity, which in turn contributes to Alzheimer’s disease progression.

🔗 nature.com/articles/s4159…

Exciting to see cerebral amyloid angiopathy (CAA) gaining attention in @alzforum #AAIC25 roundup, particularly highlighting Alpana Singh's work using NULISA @AlamarBio technology.
@BannerAlzheimer

lnkd.in/dcSGwyyg

Yesterday, we joined >600 dementia researchers, clinicians & students at the #Arizona #Alzheimer consortium (AAC) annual conference

We presented our latest work on fully-automated blood biomarker tests for #AD & discovery proteomics for non-AD pathologies. @BannerAlzheimer

Excited to invite you to our featured research session on remote biomarker collection in Alzheimer's disease— TODAY (Monday) 2 PM in Hall F #AAIC25!

We’ll highlight diverse blood sampling methods, app-based cognitive and speech monitoring.

I’m delighted & tremendously proud to attend my first #AAIC as a principal investigator alongside my incredible team.

We invite you to attend our oral presentations, sessions, and poster discussions—please stop by and engage with our work! hashtag #AAIC2025 @alzassociation

"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/10.1002/an…

#ENDALZ @FNIH_Org

🚨 In this paper in @NatureCommuniations, we find that Down syndrome #Alzheimer exhibits unique pathological features compared with sporadic late-onset and autosomal dominant AD with important implications for treatment strategies.

nature.com/articles/s4146…